Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Lasolvan or Mucoangin. The substance is a mucoactive drug with several properties including secretolytic and secretomotoric actions that restore the physiological clearance mechanisms of the respiratory tract which play an important role in the body’s natural defence mechanisms. It stimulates synthesis and release of surfactant by type II pneumocytes. Surfactants acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents.
Ambroxol is indicated for secretolytic therapy in bronchoplmonary disease with abnormal mucus secretion and transport. It allows the mucus to be more easily cleared and ease a patient's breathing.
Parkwood Institute, London, Ontario, Canada
Samsung medical center, Seoul, Korea, Republic of
ExSAR Corporation, Monmouth Junction, New Jersey, United States
Boehringer Ingelheim Investigational Site, Wuhan, China
ENT Subsidiary of Fudan University Hospital, Shanghai, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.